Factors Influencing Immunotherapy Response in Neuroblastoma: From Tumor Microenvironment to Combination Strategies
Cells · 28.02.2026 · 15 (5) · 441
DOI: 10.3390/cells15050441 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 28.02.2026. Verfasst von Xiaoran Du und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Surgery, Children's Hospital of Fudan University, Shanghai 201102, China. Hauptthemen laut MEDLINE: Neuroblastoma, Tumor Microenvironment, Immunotherapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cyrus Tang Foundation, National Natural Science Foundation of China, the Shanghai Hospital Development Center Foundation.
Abstract (Originalsprache)
Neuroblastoma is the most common extracranial solid tumor in children, and the prognosis for high-risk patients remains dismal. Immunotherapies, represented by anti-GD2 monoclonal antibodies and chimeric antigen receptor T cells (CAR-T), have significantly improved the survival of high-risk neuroblastoma patients and become part of standard therapy. However, their efficacy exhibits significant inter-individual heterogeneity, with some patients showing primary resistance or secondary relapse. This review aims to analyze the multi-faceted factors influencing the response to immunotherapy in neuroblastoma, including: (1) the inherent immunosuppressive properties of the tumor microenvironment, such as infiltration of myeloid-derived suppressor cells and tumor-associated macrophages, as well as checkpoint molecules and metabolic barriers; (2) tumor cell-intrinsic characteristics, such as low tumor mutational burden, MYCN amplification-associated downregulation of MHC-I, and heterogeneity of GD2 antigen expression; (3) host factors, such as systemic immune status and Fc receptor polymorphisms; and (4) treatment-related factors, such as combination strategies and the development of novel immunotherapeutic products. A deep understanding of these interrelated factors is crucial for developing predictive biomarkers, designing novel combination strategies and next-generation immunotherapies, and ultimately achieving precise immunotherapy for neuroblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Surgery, Children's Hospital of Fudan University, Shanghai 201102, China.
- Shanghai Key Laboratory of Birth Defect, Children's Hospital of Fudan University, Shanghai 201102, China.
ORCID-Profile: Rui Dong
Förderung
- Cyrus Tang Foundation
- National Natural Science Foundation of China
- the Shanghai Hospital Development Center Foundation
- Science and Technology Commission of Shanghai Municipality
- Cao'e River Basic Research Fund of Fudan University
- Shanghai Hospital Development Center Foundation
- Cao’e River Basic Research Fund of Fudan University
Zitieren
APA
Du, X., Dong, R., & Dong, K. (2026). Factors Influencing Immunotherapy Response in Neuroblastoma: From Tumor Microenvironment to Combination Strategies. Cells, 15(5), 441. https://doi.org/10.3390/cells15050441
Vancouver
Du X, Dong R, Dong K. Factors Influencing Immunotherapy Response in Neuroblastoma: From Tumor Microenvironment to Combination Strategies. Cells. 2026;15(5):441. doi:10.3390/cells15050441
BibTeX
@article{Du2026,
author = {Du, Xiaoran and Dong, Rui and Dong, Kuiran},
title = {Factors Influencing Immunotherapy Response in Neuroblastoma: From Tumor Microenvironment to Combination Strategies},
journal = {Cells},
year = {2026},
volume = {15},
number = {5},
pages = {441},
doi = {10.3390/cells15050441}
}
EUVIMED